Erasca, Inc. (ERAS): Total Assets
$396.15M
As of 2025-12-31
$435.05M
As of 2026-06-30
-8.4%
3-year compound annual growth
+26.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $396.15M | -21.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $502.53M | +27.1% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $395.30M | -23.2% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $514.91M | +2.7% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $501.42M | +301.7% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $124.83M | n/a | 2022-03-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Erasca, Inc. (ERAS) | 2025-12-31 | $396.15M | -21.2% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $396.90M | +13.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $398.69M | +26.0% |
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | $393.09M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $399.48M | +2.7% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $404.21M | -19.4% |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $385.14M | +43.4% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $408.89M | +49.2% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $383.64M | +3.7% |
Compare ERAS, IRWD, TNGX, OTLC side by side · Screen every company in Pharmaceutical Preparations ↗